Motif Bio (MTFB) Stock Price, News & Analysis

Company Overview

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Key Stats

• Today's Range: $0.10 to $0.12
• 50-Day Range: $0.10 to $0.11
• 52-Week Range: $0.08 to $11.50
• Volume: 867,698 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MTFB Stock Analysis - Frequently Asked Questions

When did Motif Bio IPO?

Motif Bio (MTFB) raised $17 million in an initial public offering on Friday, November 18th 2016. The company issued 2,400,000 shares at $6.98 per share. H.C. Wainwright & Co. acted as the underwriter for the IPO.

What other stocks do shareholders of Motif Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Motif Bio investors own include Sorrento Therapeutics (SRNE), Allergan (AGN), Ampliphi Biosciences (APHB), Neurocrine Biosciences (NBIX), Bristol Myers Squibb (BMY), Canopy Growth (CGC) and Forward Pharma A/S (FWP).

Company Calendar

• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MTFB
• CIK: 1674657
• Web: www.motifbio.com
• Phone: 212-210-6248
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A